1 Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011).

2 Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer genomes through second-generation sequencing. Nature Rev. Genet. 11, 685–696 (2010).

3 Freedman, M. L. et al. Principles for the post-GWAS functional characterization of cancer risk loci. Nature Genet. 43, 513–518 (2011).

4 Hanash, S. & Taguchi, A. The grand challenge to decipher the cancer proteome. Nature Rev. Cancer 10, 652–660 (2010).

5 Brough, R. et al. Functional viability profiles of breast cancer. Cancer Discov. 1, 260–273 (2011).

6 Hoon, S. et al. An integrated platform of genomic assays reveals small-molecule bioactivities. Nature Chem. Biol. 4, 498–506 (2008).

7 Workman, P. & Collins, I. Probing the probes: fitness factors for small molecule tools. Chem. Biol. 17, 561–577 (2010).

8 Chin, L., Hahn, W. C., Getz, G. & Meyerson, M. Making sense of cancer genomic data. Genes Dev. 25, 534–555 (2011).

9 Garraway, L. A. & Jänne, P. A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214–226 (2012).

10 Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306–313 (2012).

11 Stratton, M. R. Exploring the genomes of cancer cells: progress and promise. Science 331, 1553–1558 (2011).

12 Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotech. 30, 679–692 (2012).

13 de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

14 Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).

15 Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).

16 Pammolli, F., Magazzini, L. & Riccaboni, M. The productivity crisis in pharmaceutical R&D. Nature Rev. Drug Discov. 10, 428–438 (2011).

17 Yap, T. A. & Workman, P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu. Rev. Pharmacol. Toxicol. 52, 549–573 (2012).

18 Edfeldt, F. N., Folmer, R. H. & Breeze, A. L. Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Discov. Today 16, 284–287 (2011).

19 Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005).

20 Verdine, G. & Walensky, L. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13, 7264–7270 (2007).

21 Hudson, T. J. et al. International network of cancer genome projects. Nature 464, 993–998 (2010).

22 Iorns, E., Lord, C. J., Turner, N. & Ashworth, A. Utilizing RNA interference to enhance cancer drug discovery. Nature Rev. Drug Discov. 6, 556–568 (2007).

23 Aguero, F. et al. Genomic-scale prioritization of drug targets: the TDR Targets database. Nature Rev. Drug Discov. 7, 900–907 (2008).

24 Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100–D1107 (2012).

25 Halling-Brown, M. D. Bulusu, K.C., Patel, M., Tym, J.E. & Al-Lazikani, B. canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res. 40, D947–D956 (2012).

26 Begley, C. G. & Ellis, L. M. Drug development: raise standards for preclinical cancer research. Nature 483, 531–533 (2012).

27 Prinz, F., Schlange, T. & Asadullah, K. Believe it or not: how much can we rely on published data on potential drug targets? Nature Rev. Drug Discov. 10, 712 (2011).

28 Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177–183 (2004).

29 Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nature Rev. Drug Discov. 5, 993–996 (2006).

30 Darnell, J. E. Transcription factors as targets for cancer therapy. Nature Rev. Cancer 2, 740–749 (2002).

31 Moellering, R. E. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182–188 (2009).

32 Wang, C.-Y., Mayo, M. W. & Baldwin, A. S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science 274, 784–787 (1996).

33 Yu, H. & Jove, R. The STATs of cancer — new molecular targets come of age. Nature Rev. Cancer 4, 97–105 (2004).

34 Seth, A. & Watson, D. K. ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 41, 2462–2478 (2005).

35 Jones, K. A. Outsmarting a mastermind. Dev. Cell 17, 750–752 (2009).

36 Faisal, A. et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol. Cancer Ther. 10, 2115–2123 (2011).

37 Berriman, M. et al. The genome of the blood fluke Schistosoma mansoni. Nature 460, 352–358 (2009).

38 Dudley, J. T. et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 3, 96ra76 (2011).

39 Sanseau, P. et al. Use of genome-wide association studies for drug repositioning. Nature Biotech. 30, 317–320 (2012).

40 Kato, Y. et al. PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kB signaling pathway. Oncogene 25, 2736–2747 (2005).

41 Copland, J. A. et al. Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1//CIP1. Oncogene 25, 2304–2317 (2005).

42 Demetri, G. D. et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc. Natl Acad. Sci. USA 96, 3951–3956 (1999).

43 Russo, D. et al. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. J. Clin. Endocrinol. Metab. 81, 1548–1551 (1996).

44 Parma, J. et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365, 649–651 (1993).

45 Polak, M. Hyperfunctioning thyroid adenoma and activating mutations in the TSH receptor gene. Arch. Med. Res. 30, 510–513 (1999).

46 Milas, M. et al. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Ann. Surg. Oncol. 16, 473–480 (2009).

47 Neumann, S. et al. A low-molecular-weight antagonist for the human thyrotropin teceptor with therapeutic potential for hyperthyroidism. Endocrinology 149, 5945–5950 (2008).

48 Neumann, S. et al. A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. Endocrinology 151, 3454–3459 (2010).

49 Sekulic, A. et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 366, 2171–2179 (2012).

50 The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).

51 Friedberg, J. W. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 2578–2585 (2010).

52 Zhang, J. et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481, 329–334 (2012).

53 Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997).

54 Yuan, Y., Liao, Y. M., Hsueh, C. T. & Mirshahidi, H. R. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J. Hematol. Oncol. 4, 16 (2011).

55 Surade, S. & Blundell, T. L. Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem. Biol. 19, 42–50 (2012).

56 Collins, I. & Workman, P. New approaches to molecular cancer therapeutics. Nature Chem. Biol. 2, 689–700 (2006).

57 Balamurugan, K. et al. The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J. 29, 4106–4117 (2010).

58 Yang, L., Han, Y., Suarez Saiz, F. & Minden, M. D. A tumor suppressor and oncogene: the WT1 story. Leukemia 21, 868–876 (2007).

59 Ueno, N. T., Yu, D. & Hung, M. C. E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. Breast Cancer 8, 285–293 (2001).

60 Wilson, J. J. & Kovall, R. A. Crystal structure of the CSL-Notch-mastermind ternary complex bound to DNA. Cell 124, 985–996 (2006).

61 Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).

62 Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).

63 DeAngelis, L. M. & Mellinghoff, I. K. Virchow 2011 or how to ID(H) human glioblastoma. J. Clin. Oncol. 29, 4473–4474 (2011).

64 Bolton, E. E., Wang, Y., Thiessen, P. A. & Bryant, S. H. PubChem: integrated platform of small molecules and biological activities. Annu. Rep. Comput. Chem. 4, 217–241 (2008).

65 Smith, T. M., Hicks-Berger, C. A., Kim, S. & Kirley, T. L. Cloning, expression, and characterization of a soluble calcium-activated nucleotidase, a human enzyme belonging to a new family of extracellular nucleotidases. Arch. Biochem. Biophys. 406, 105–115 (2002).

66 Hermans, K. G. et al. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res. 68, 3094–3098 (2008).

67 Gerhardt, J. et al. The androgen-regulated calcium-activated nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro. Am. J. Pathol. 178, 1847–1860 (2011).

68 Medina, P. P. et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum. Mutat. 29, 617–622 (2008).

69 Alessio, N. et al. The BRG1 ATPase of chromatin remodeling complexes is involved in modulation of mesenchymal stem cell senescence through RB-P53 pathways. Oncogene 29, 5452–5463 (2010).

70 Sentani, K. et al. Increased expression but not genetic alteration of BRG1, a component of the SWI/SNF complex, is associated with the advanced stage of human gastric carcinomas. Pathobiology 69, 315–320 (2001).

71 Emmanuel, C. et al. Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS ONE 6, e17617 (2011).

72 Hindorff, L. A. et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 106, 9362–9367 (2009).

73 Verdine, G. L. in The Harvey Lectures: Series 102, 2006–2007 1–16 (Wiley-Blackwell; 2010).

74 Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).

75 Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235–242 (2000).

76 Halgren, T. New method for fast and accurate binding-site identification and analysis. Chem. Biol. Drug Des. 69, 146–148 (2007).

77 Luangdilok, S. et al. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res. 67, 7907–7916 (2007).

78 Vidler, L. R., Brown, N., Knapp, S. & Hoelder, S. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J. Med. Chem. 55, 7346–7359 (2012).

79 Chen, X., Lin, Y., Liu, M. & Gilson, M. K. The Binding Database: data management and interface design. Bioinformatics 18, 130–139 (2002).

80 Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nature Rev. Cancer 6, 813–823 (2006).

81 Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403–410 (1990).